

INTERIM REPORT

JANUARY 1 - SEPTEMBER 30, 2026

**The positive development in the companies continues,
and the pace of acquisitions is increasing**



The positive development across AddLife's companies continues, with stronger margins, solid growth and improved cash flow. The operational improvements and strengthened balance sheet have enabled increased acquisition activity, something we have been preparing for a long time.

Fredrik Dalborg, President and CEO

THIRD QUARTER

- Net sales increased by 7 percent to SEK 2,599 million (2,429). Adjusted for operations divested in December 2025, organic growth amounted to 4 percent and acquired growth amounted to 3 percent.
- Adjusted EBITA increased by 11 percent to 298 (270), corresponding to an adjusted EBITA margin of 11.5 percent (11.1). Adjusted EBITA excludes the remeasurement of contingent considerations of SEK 32 million.
- EBITA amounted to SEK 330 million (270).
- Profit after tax increased by 56 percent to SEK 128 million (82).
- Earnings per share amounted to SEK 1.05 (0.66).
- Cash flow from operating activities increased by 62 percent to SEK 236 million (145).
- During the quarter, the acquisition of Unicom Sistemas Analíticos Lda, Portugal, was completed. The acquisition is expected to contribute annual net sales of approximately SEK 110 million.
- After the end of the interim period, the acquisition of Lehnen GmbH, Germany, was completed. The acquisition is expected to contribute annual net sales of approximately SEK 55 million.

JANUARY – SEPTEMBER, 2026

- Net sales increased by 3 percent to SEK 7,965 million (7,709). Adjusted for operations divested in December 2025, organic growth amounted to 4 percent, acquired growth amounted to 2 percent.
- Adjusted EBITA increased by 6 percent to 972 (920), corresponding to an adjusted EBITA margin of 12.2 percent (11.9). Adjusted EBITA excludes the remeasurement of contingent considerations of SEK 32 million.
- EBITA amounted to SEK 1,004 million (920).
- Profit after tax increased by 28 percent to SEK 386 million (302).
- Earnings per share amounted to SEK 3.15 (2.47). For the latest 12-month period, earnings per share amounted to 5.28 (3.23).
- Cash flow from operating activities amounted to SEK 505 million (504).
- The equity ratio was 44 percent (43).
- Return on working capital (P/WC) amounted to 63 percent (62).
- Three acquisitions were completed during and one acquisition after the interim period. The acquisitions are expected to contribute annual net sales of approximately SEK 350 million.

SEKm	Q3 2026	Q3 2025	Δ %	Jan-Sep 2026	Jan-Sep 2025	Δ %	Oct 2025- Sep 2026	Full year 2025
Net sales	2,599	2,429	7	7,965	7,709	3	10,698	10,442
EBITA	330	270	22	1,004	920	9	1,501	1,417
EBITA margin, %	12.7	11.1		12.6	11.9		14.0	13.6
Adjusted EBITA	298	270	11	972	920	6	1,311	1,259
Adjusted EBITA margin, %	11.5	11.1		12.2	11.9		12.3	12.1
Profit/loss before taxes	179	111	61	551	429	28	894	772
Profit for the period	128	82	56	386	302	28	646	562
Earnings per share (EPS), before/after dilution, SEK	1.05	0.66	59	3.15	2.47	28	5.28	4.59
Cash flow from operating activities	236	145	62	505	504	0	1,393	1,392

4 %

ORGANIC GROWTH

11 %

EBITA GROWTH

11.5 %

EBITA MARGIN

63 %

P/WC

The positive development in the companies continues, and the pace of acquisitions is increasing

"The positive development across AddLife's companies continues, with stronger margins, solid growth and improved cash flow. The operational improvements and strengthened balance sheet have enabled increased acquisition activity, something we have been preparing for a long time."

Fredrik Dalborg, President and CEO



Good sales growth

AddLife's sales increased by 7 percent during the quarter, with positive development in both Labtech and Medtech. The increased pace of acquisitions made a clear contribution to growth. The customer activity is normally lower during the summer month, particularly within elective surgery and research, and deliveries of larger instruments and capital goods are also often lower. In Spain, healthcare labor disputes continued to hold back demand during the quarter. Despite this, growth was healthy, driven by dedicated and structured sales efforts as well as the continuous introduction of new, advanced products. Sales development in the Nordic region was stable, while growth increased in the UK and Ireland. In Eastern Europe, growth was strong, driven by sound underlying economic development and increased investments in healthcare and research. In September, customer activity increased again, leading to higher demand and stronger order intake.

Margins continue to improve

Strengthening margins and increasing profit is our highest financial priority. Margins strengthened during the quarter and total profit growth was good. We can clearly see that the introduction of new advanced products contributes to improved gross margins. These products sometimes also require investments in qualified resources, but this is offset by the higher gross margins.

Offering new technologies and advanced products is a clear focus area in all our companies. Market conditions for introducing new products that improve the efficiency of research and healthcare processes are favourable. At the same time, we see that established product companies are increasingly moving towards distributor models, while companies with new and innovative technologies are seeking distribution partners.

The pace of acquisitions has increased

Following a period in which the main focus has been on organic improvement initiatives and strengthening the balance sheet, AddLife has now entered a new phase with increased acquisition activity. The number of acquisitions has increased from one per year in 2023 and 2024 to three in 2025. Lehnén was acquired in October, bringing the number of acquisitions to six over the past twelve-month period.

Before the summer, CoaChrom and BioSpectrum were acquired, and during the past two months Unicam and Lehnén have been acquired. These companies meet our acquisition criteria well, operate within our prioritised product segments, and have margins that are clearly above our current average. We warmly welcome these companies to the AddLife family.

For some time, we have strengthened our resources for driving acquisition processes and have established a clear allocation of responsibilities. A number of acquisition processes are being pursued in parallel, and we are working in a structured and long-term manner with our acquisition pipeline.

Our decentralised model creates motivation, results and acquisition opportunities

Decentralised responsibility is a very important part of our well-established and proven business model. The companies within AddLife retain their own brands and identity, while also having responsibility for their own strategy, operations and results. Quick decision-making processes and local mandates create motivated teams with a strong customer focus and a strong ability to quickly adapt to local markets and new trends. With the Group's operations spread across Europe, the decentralised structure also contributes to natural resilience within the Group.

AddLife actively promotes decentralisation within its companies and, in recent years, has divided larger companies into more focused divisions and removed costly central functions. This has resulted in increased growth and improved margins.

The decentralised model, combined with deep industry knowledge and an extensive network, also makes AddLife an attractive partner for entrepreneurs and a long-term home for successful companies.

Summary and outlook

The clear and evident positive development continues in AddLife's companies, with strengthened margins, good growth and improved cash flow. The operational improvements and strengthened balance sheet have enabled increased acquisition activity, which has been prepared over an extended period.

We now see a clearly increased pace of acquisitions and are pleased to welcome more new companies to the AddLife family. A warm thanks to all employees for valuable contributions and strong commitment. Development in our companies is positive and market trends are favourable. We look forward to building further on this during the fourth quarter of the year.

Stockholm, October 21, 2026



Fredrik Dalborg
President and CEO



THIRD QUARTER


Net sales increased by 7 percent to SEK 2,599 million (2,429). Organic growth amounted to 3 percent and acquired growth to 3 percent. Organic growth was negatively impacted by the divestment of the endoscopy operations in the United Kingdom in December 2025, corresponding to SEK 27 million. Adjusted for the divestment, organic growth amounted to 4 percent. Exchange rate effects had a positive impact on net sales of SEK 24 million, corresponding to 1 percent.

Adjusted EBITA increased by 11 percent to SEK 298 million (270), corresponding to an adjusted EBITA margin of 11.5 percent (11.1). Adjusted EBITA excludes the remeasurement of contingent consideration of SEK 32 million. Exchange rate effects had a marginal impact on EBITA.


Net financial items amounted to SEK -42 million (-54) and profit after financial items totalled SEK 179 million (111). Net financial items primarily include interest expenses related to the financing of previous acquisitions as well as exchange rate effects. Interest expenses amounted to SEK 46 million (47) and exchange rate gains to SEK 3 million (5).

Profit after tax increased by 56 percent to SEK 128 million (82), and the effective tax rate was 28 percent (29). The slightly high effective tax rate is attributable to the effect of non-deductible interest expenses.


Net sales quarter




EBITA quarter



Net sales



Adjusted EBITA



JANUARY – SEPTEMBER, 2026


Net sales increased by 3 percent to SEK 7,965 million (7,709). Growth, excluding exchange rate effects, amounted to 4 percent, of which organic growth was 2 percent and acquired growth was 2 percent. Organic growth was negatively impacted by the divestment of the endoscopy business in the UK in December 2025, corresponding to SEK 120 million. Adjusted for the divestment, organic growth amounted to 4 percent. Exchange rate effects had a negative impact on net sales of SEK 89 million, corresponding to 1 percent.

Adjusted EBITA increased by 6 percent to SEK 972 million (920), corresponding to an adjusted EBITA margin of 12.2 percent (11.9). Adjusted EBITA excludes the remeasurement of contingent consideration of SEK 32 million. Currency effects had a negative impact on EBITA of SEK 9 million, corresponding to 1 percent.


Net financial items amounted to SEK -135 million (-171) and profit after financial items totalled SEK 551 million (429). Net financial items mainly include interest expenses related to the financing of previous acquisitions as well as exchange rate fluctuations. Interest expenses amounted to SEK 133 million (156) and exchange rate losses to SEK 9 million (6).

Profit after tax increased by 28 percent to SEK 386 million (302), and the effective tax rate was 30 percent (30). The slightly high effective tax rate is attributable to the effect of non-deductible interest expenses.

Net sales January – September



EBITA January – September



Financial position and cash flow

The equity ratio at the end of the interim period was 44 percent (43). Equity per share amounted to SEK 48.86 (44.67) and return on equity at the end of the interim period was 11 percent (11). Return on working capital (P/WC) was 63 percent (62).

The Group's net interest-bearing debt at the end of the interim period amounted to SEK 4,746 million (4,048), including pension liabilities of SEK 57 million (58), lease liabilities of SEK 571 million (504), contingent considerations corresponding to SEK 225 million (124) and provisions corresponding to SEK 27 million (29). Outstanding bank borrowings at the end of the interim period amounted to SEK 4,343 million (4,146), and were classified as current due to the remaining maturity. Subsequent to the end of the interim period, the company refinanced its existing bank facilities with a three-year term and two one-year extension options.


Available liquidity, consisting of cash and bank balances, together with granted but unutilised credit facilities, amounted in total to SEK 1,450 million (1,447) at the end of the interim period.

The net debt/equity ratio was 0.8, compared with 0.7 at the beginning of the year.


Cash flow from operating activities amounted to SEK 236 million (145) during the quarter and to SEK 505 million (504) during the interim period. The increase during the quarter was primarily attributable to lower working capital tied up compared with the previous year. In total, the change in working capital during the quarter amounted to SEK -58 million (-143). During the interim period, payments for company acquisitions totalled SEK 377 million (164) and paid contingent considerations related to company acquisitions from previous years amounted to SEK 23 million (51). Net investments in non-current assets amounted to SEK 205 million (180), primarily related to investments in instruments placed with customers. A dividend of SEK 182 million (91) was paid to the Parent Company's shareholders.

Long term financial goals

Profitability P/WC (%)



Profit growth adjusted EBITA (%)



Employees

At the end of the interim period, the number of employees was 2,428, compared to 2,295 at the beginning of the financial year. During the interim period, the completed acquisitions have led to an increase of 46 employees. The average number of employees for the last 12-month period was 2,336 (2,296).

Acquisitions

Acquisitions completed from the 2025 financial year are distributed among the Group's business areas as follows:

Company	Country	Time	Net Sales, SEKm*	Number of employees*	Business area
Edge Medical Ltd.	UK	April 2025	90	20	Medtech
Pharmacold A/S	Denmark	December 2025	38	20	Labtech
Opitek International ApS	Denmark	December 2025	12	2	Medtech
BioSpectrum Ltd.	UK	March 2026	75	16	Medtech
CoaChrom Diagnostica GmbH	Austria	April 2026	110	10	Labtech
Unicam Sistemas Analíticos Lda	Portugal	September 2026	110	20	Labtech
			435	88	

*Refers to conditions at the time of acquisition on a full-year basis.

In March all shares in BioSpectrum Ltd., United Kingdom, were acquired. BioSpectrum is a rapidly growing distributor of surgical solutions within urology, gynaecology and general surgery in the UK market. The company has annual sales of approximately GBP 6 million and 16 employees.

In April all shares in the Austrian company CoaChrom Diagnostica GmbH were acquired. CoaChrom is a distributor focusing on advanced coagulation diagnostics for clinical laboratories and the pharmaceutical industry. The company has annual sales of approximately EUR 10 million and 10 employees.

In September, all shares in the Portuguese company Unicam Sistemas Analíticos Lda were acquired. Unicam distributes advanced analytical laboratory equipment to universities, research institutes and industrial customers. The company has annual revenue of approximately EUR 10 million and 20 employees.

Net assets of acquired companies at the acquisition date

Fair value SEKm	Sep 30 2026
Intangible non-current assets	183
Other non-current assets	11
Inventories	42
Other current assets	134
Deferred tax liability/tax asset	-41
Other liabilities	-82
Acquired net assets	247
Goodwill	337
Consideration¹	584
Less:	
Cash and cash equivalents in acquired businesses	-65
Contingent consideration not yet paid	-142
Effect on the Group's cash and cash equivalents	377

¹The consideration is stated excluding acquisition expenses.

Acquired companies

The purchase price allocations are preliminary, as the net assets of the acquired companies have not yet been finally determined. For this year's acquisitions, the purchase consideration exceeded the carrying amount of the net assets of the acquired companies, resulting in goodwill and intangible assets.

Goodwill

The goodwill arising from the acquisitions is attributable to the expectation that the Group's position in the relevant markets will be strengthened, as well as the expertise developed in the acquired companies.

Contingent consideration

The contingent considerations included in the acquisitions are usually linked to the performance development of the respective companies.

During the interim period, contingent consideration of SEK 23 million relating to acquisitions completed in previous years was paid to the sellers of BonsaiLab, Pharmacold and Opitek.

Remeasurement of liabilities for contingent consideration relating to previous acquisitions resulted in a net income of SEK 32 million. These were reversed during the quarter and recognized in other operating income and expenses.

Transaction costs

Transaction costs for acquisitions amount to a total of SEK 5 million and are recognized in selling expenses.

Revenue and earnings from acquired businesses

The acquisitions completed during the year have, from their respective acquisition dates, contributed a total of SEK 114 million to the Group's net sales and SEK 36 million to EBITA.

Had the acquired companies been consolidated from January 1, 2026, net sales and EBITA would have amounted to SEK 293 million and SEK 91 million, respectively.

Acquisitions after the end of the interim period

In October, 85 percent of the shares in the German company Lehen GmbH were acquired. Lehen manufactures products and system solutions for accessible and functionally adapted bathrooms. The company has annual sales of approximately EUR 5 million and around 30 employees.

Labtech

The Labtech business area provides products, solutions and services in fields such as diagnostics, biomedical research and laboratory analysis. The business area consists of two business units: Biomedical and Research and Diagnostics. The most important customer groups are hospital laboratories, academic research and pharmaceutical companies in Europe.




SEKm	Q3 2026	Q3 2025	Δ %	Jan-Sep 2026	Jan-Sep 2025	Δ %	Oct 2025- Sep 2026	Full year 2025
Net sales	983	906	8	3,025	2,880	5	4,098	3,953
Organic growth, %	2	9		2	9			5
EBITA	115	102	14	386	343	12	538	495
EBITA margin, %	11.7	11.2		12.8	11.9		13.1	12.5
Adjusted EBITA	126	102	24	397	343	16	549	495
Adjusted EBITA margin, %	12.9	11.2		13.1	11.9		13.4	12.5

THIRD QUARTER

Net sales in Labtech increased by 8 percent to 983 million (906). Organic growth amounted to 2 percent and acquired growth to 5 percent. Exchange rate effects had a positive impact on net sales of SEK 10 million, corresponding to 1 percent.

Adjusted EBITA increased by 24 percent to SEK 126 million (102), corresponding to an adjusted EBITA margin of 12.9 percent (11.2). Adjusted EBITA excludes the remeasurement of contingent considerations, which amounted to SEK -11 million. Exchange rate effects had a positive impact of SEK 2 million on EBITA, corresponding to 2 percent.

Net sales quarter




JANUARY – SEPTEMBER, 2026

Labtech's net sales increased by 5 percent to SEK 3,025 million (2,880). Adjusted for exchange rate effects, net sales increased by 6 percent, of which organic growth increased by 2 percent and acquired growth amounted to 4 percent. Exchange rate effects had a negative impact on net sales of SEK 20 million, corresponding to 1 percent.

Adjusted EBITA increased by 16 percent to SEK 397 million (343), corresponding to an adjusted EBITA margin of 13.1 percent (11.9). Adjusted EBITA excludes the remeasurement of contingent considerations, which amounted to SEK -11 million. Exchange rate effects had a negative impact of SEK 1 million on EBITA, corresponding to 0 percent.


Net sales January – September




Labtech performed well during the quarter, both organically and with a clear contribution from acquisitions. Within diagnostics, demand remained stable and strong, particularly in blood gas analysis, pathology, point-of-care testing, molecular diagnostics, automation, service and specialized coagulation. Within research, activity was seasonally lower during the summer, primarily due to a lower level of instrument deliveries. Development in Eastern Europe remained strong, driven by solid underlying market growth and investments in advanced technology. Several new products were added to the portfolio during the quarter, including products within immunohematology and transfusion medicine, which are expected to contribute to further growth going forward.

The business in Southern Europe was strengthened through the acquisition of Unicam, a distributor of advanced laboratory equipment to universities, research institutes and industrial customers.


Net sales




Net sales per market January – September 2026



Adjusted EBITA



Adjusted EBITA margin (%)



Medtech

In the Medtech business area, the subsidiaries offer products and services in the field of medical technology, as well as assistive equipment and digital solutions for home care. Medtech has two business units, Hospital and Homecare. The Medtech offering mainly focuses on publicly funded healthcare, home care and social care in Europe.




SEKm	Q3 2026	Q3 2025	Δ %	Jan-Sep 2026	Jan-Sep 2025	Δ %	Oct 2025- Sep 2026	Full year 2025
Net sales	1,617	1,524	6	4,944	4,832	2	6,607	6,495
Organic growth, %	4	4		2	2			2
EBITA	226	177	27	651	607	7	1,008	964
EBITA margin, %	14.0	11.6		13.2	12.6		15.3	14.8
Adjusted EBITA	183	177	3	608	607	0	806	805
Adjusted EBITA margin, %	11.3	11.6		12.3	12.6		12.2	12.4

THIRD QUARTER

Net sales in Medtech increased by 6 percent to SEK 1,617 million (1,524). Organic growth amounted to 4 percent and acquired growth to 1 percent. Organic growth was negatively impacted by the divestment of the endoscopy business in the UK in December 2025, corresponding to approximately SEK 27 million. Adjusted for the divestment, organic growth amounted to 5 percent. Exchange rate effects had a positive impact on net sales of SEK 17 million, corresponding to 1 percent.

Adjusted EBITA increased by 3 percent to SEK 183 million (177), corresponding to an adjusted EBITA margin of 11.3 percent (11.6). Adjusted EBITA excludes the remeasurement of contingent considerations, which amounted to SEK 43 million. Exchange rate effects had a positive impact on EBITA of SEK 2 million, corresponding to 1 percent.

Net sales quarter




JANUARY – SEPTEMBER, 2026

Medtech's net sales amounted to SEK 4,944 million (4,832). Adjusted for exchange rate effects, net sales increased by 4 percent, of which organic growth amounted to 2 percent and acquired growth to 2 percent. Organic growth was negatively impacted by the divestment of the endoscopy business in the UK in December 2025, corresponding to approximately SEK 120 million. Adjusted for the divestment, organic growth amounted to 5 percent. Exchange rate effects had a negative impact on net sales of SEK 68 million, corresponding to 1 percent.

Adjusted EBITA increased marginally to SEK 608 million (607), corresponding to an adjusted EBITA margin of 12.3 percent (12.6). Adjusted EBITA excludes the remeasurement of contingent considerations, which amounted to SEK 43 million. Exchange rate effects had a negative impact on EBITA of SEK 9 million, corresponding to 1 percent.

Net sales January – September




Medtech grew in line with the market during the quarter, with acquisitions also contributing to growth. The number of planned surgical procedures is normally lower during the summer months, which was also the case this year, particularly within hospital products and ophthalmic surgery.


Growth in the Nordic region was good. In Spain, development continued to be affected by the impact of healthcare labor disputes, but growth remained good in spite of this. In the UK, the number of surgical procedures performed increased compared with the previous year, while capital equipment ordered during the previous quarter was delivered.

Homecare continues to develop well. Through the acquisition of Lehnen, the business outside the Nordics is strengthened and the portfolio is expanded with additional in-house manufactured products.

Net sales




Net sales per market January– September 2026



Adjusted EBITA



Adjusted EBITA margin (%)



Decentralisation is part of our DNA

AddLife's business model is based on local entrepreneurship, clear responsibility and proximity to customers and suppliers. Our decentralised structure gives the subsidiaries the freedom to develop their operations based on local market conditions and their own strengths, while benefiting from the Group's experience, network and financial stability. Decentralisation is part of our DNA and characterises how we build and develop our companies over time.

In recent years, we have simplified structures, moved responsibility closer to the operations and clarified responsibility for business performance. This has created a more focused and business-oriented organisation with better conditions for organic growth, more efficient capital use and improved margins.

The development is evident in several of our larger platforms. Within HC21, operations in the UK and Ireland have been given clearer local responsibility. Within MBA, a previously shared commercial organisation has been split into three specialised divisions: Within AddVision, the central Group functions have been discontinued, and responsibility has been transferred to five local companies.

Our decentralised model is a strength in our acquisition activities. With a clear acquisition responsibility given to the business unit leaders, acquisition activities move closer to the market and strengthen our ability to identify and develop companies that fit AddLife's culture, selected niches and long-term growth ambitions.

Together, local entrepreneurship, clear responsibility for business performance and active Group support contribute to a more efficient and motivated organisation. This strengthens AddLife and creates good conditions for continued profitable growth.




Value for AddLife and the subsidiaries

- **The subsidiaries** have the freedom to act close to customers and suppliers, while benefiting from the Group's strength, network and experience.
- **M&A** is driven by the responsible business unit leaders, with support from experienced advisers and resources from the subsidiaries.
- **Decentralisation** attracts and retains talent. The decentralised model is motivating for team members, offers growth opportunities and attracts individuals and acquisition targets.

MBA

SURGICAL EMPOWERMENT

From one commercial organisation to three specialised divisions: Orthopaedics & Trauma; Neuro, Oncology, Spine & Biologics; and Anaesthesia & Surgery.



HC21

YOUR TRUSTED MEDTECH PARTNER


From a joint organisation for the UK and Ireland to country-specific organisations with specialised commercial divisions.



AddVision

BRINGING GREATER VISION TO EVERYONE

From central Group functions to five local companies: one in Poland, one in Switzerland, one in the UK and two in Germany.



Quarterly data

Net sales by business area

SEKm	2024		2025				2026		
	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
Labtech	852	1,141	989	985	906	1,073	985	1,057	983
Medtech	1,494	1,679	1,714	1,594	1,524	1,663	1,661	1,666	1,617
Group items	-2	-2	-1	-1	-1	-3	-1	-2	-1
The Group	2,344	2,818	2,702	2,578	2,429	2,733	2,645	2,721	2,599

EBITA by business area

SEKm	2024		2025				2026		
	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
Labtech	76	161	120	122	102	152	129	142	115
Medtech	153	195	231	198	177	357	212	213	226
Group items	-6	-10	-8	-13	-9	-12	-9	-13	-11
The Group	223	346	343	307	270	497	332	342	330

%	2024		2025				2026		
	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
Labtech	8.9	14.1	12.1	12.4	11.2	14.1	13.1	13.4	11.7
Medtech	10.3	11.6	13.5	12.4	11.6	21.5	12.8	12.8	14.0
The Group	9.5	12.3	12.7	11.9	11.1	18.2	12.5	12.6	12.7

Adjusted EBITA / Adjusted EBITA margin by business area

SEKm	2024		2025				2026		
	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
Labtech	76	161	120	122	102	152	129	142	126
Medtech	160	195	231	198	177	199	212	213	183
Group items	-6	-10	-8	-13	-9	-12	-9	-13	-11
The Group	230	346	343	307	270	339	332	342	298

%	2024		2025				2026		
	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3
Labtech	8.9	14.1	12.1	12.4	11.2	14.1	13.1	13.4	12.9
Medtech	10.7	11.6	13.5	12.4	11.6	12.0	12.8	12.8	11.3
The Group	9.8	12.3	12.7	11.9	11.1	12.4	12.5	12.6	11.5

Net sales and EBITA

Net sales by business area

SEKm	Q3 2026	Q3 2025	Δ %	Jan-Sep 2026	Jan-Sep 2025	Δ %	Oct 2025- Sep 2026	Full year 2025
Labtech	983	906	8	3,025	2,880	5	4,098	3,953
Medtech	1,617	1,524	6	4,944	4,832	2	6,607	6,495
Group items	-1	-1		-4	-3		-7	-6
The Group	2,599	2,429	7	7,965	7,709	3	10,698	10,442

EBITA / EBITA margin by business area and operating profit for the Group

SEKm	Q3 2026	Q3 2025	Jan-Sep 2026	Jan-Sep 2025	Oct 2025- Sep 2026	Full year 2025
Labtech	115	102	386	343	538	495
Medtech	226	177	651	607	1,008	964
Group items	-11	-9	-33	-30	-45	-42
EBITA	330	270	1,004	920	1,501	1,417
Depreciation and write-down intangible assets	-109	-105	-318	-320	-422	-424
Operating profit	221	165	686	600	1,079	993
Finance income and expenses	-42	-54	-135	-171	-185	-221
Profit after financial items	179	111	551	429	894	772


%	Q3 2026	Q3 2025	Jan-Sep 2026	Jan-Sep 2025	Oct 2025- Sep 2026	Full year 2025
Labtech	11.7	11.2	12.8	11.9	13.1	12.5
Medtech	14.0	11.6	13.2	12.6	15.3	14.8
EBITA margin	12.7	11.1	12.6	11.9	14.0	13.6
Operating margin	8.5	6.8	8.6	7.8	10.1	9.5

Net sales by revenue type

SEKm	Q3 2026	Q3 2025	Jan-Sep 2026	Jan-Sep 2025	Oct 2025- Sep 2026	Full year 2025
Products	681	631	2,148	2,066	2,877	2,795
Instruments	218	189	633	579	898	844
Services	84	86	244	235	323	314
Labtech	983	906	3,025	2,880	4,098	3,953
Products	1,338	1,258	4,111	3,974	5,499	5,362
Instruments	115	102	349	377	465	493
Services	164	164	484	481	643	640
Medtech	1,617	1,524	4,944	4,832	6,607	6,495
Group items	-1	-1	-4	-3	-7	-6
The Group	2,599	2,429	7,965	7,709	10,698	10,442

Sales per country

SEKm	Q3 2026	Q3 2025	Jan-Sep 2026	Jan-Sep 2025	Oct 2025- Sep 2026	Full year 2025
Ireland	352	328	1,009	996	1,343	1,330
Sweden	306	299	966	896	1,296	1,226
UK	320	290	933	945	1,238	1,250
Spain	231	235	805	799	1,084	1,078
Norway	179	178	622	629	821	828
Denmark	163	157	511	489	703	681
Italy	141	170	510	563	678	731
Finland	145	129	436	397	595	556
Germany	127	114	362	339	478	455
Switzerland	98	87	310	289	401	380
Rest of Europe	513	393	1,312	1,143	1,870	1,701
Rest of the World	24	49	189	224	191	226
Total	2,599	2,429	7,965	7,709	10,698	10,442



Sales by region January - September 2026

Condensed consolidated income statement

SEKm	Q3 2026	Q3 2025	Jan-Sep 2026	Jan-Sep 2025	Oct 2025- Sep 2026	Full year 2025
Net sales	2,599	2,429	7,965	7,709	10,698	10,442
Cost of sales	-1,600	-1,521	-4,869	-4,773	-6,561	-6,465
Gross profit	999	908	3,096	2,936	4,137	3,977
Selling expenses	-647	-589	-1,937	-1,867	-2,599	-2,529
Administrative expenses	-157	-145	-497	-447	-661	-611
Research and Development	-14	-14	-44	-43	-58	-57
Other operating income and expenses	40	5	68	21	260	213
Operating profit	221	165	686	600	1,079	993
Financial income and expenses	-42	-54	-135	-171	-185	-221
Profit after financial items	179	111	551	429	894	772
Tax	-51	-29	-165	-127	-248	-210
Profit for the period	128	82	386	302	646	562
<i>Attributable to:</i>						
Equity holders of the Parent Company	127	81	384	300	644	560
Non-controlling interests	1	1	2	2	2	2
Earnings per share before dilution, SEK	1.05	0.66	3.15	2.47	5.28	4.59
Earnings per share after dilution, SEK	1.05	0.66	3.15	2.47	5.28	4.59
Average number of shares after repurchases, '000s	121,864	121,864	121,864	121,864	121,864	121,864
Number of shares at end of the period, '000	121,864	121,864	121,864	121,864	121,864	121,864
EBITA	330	270	1,004	920	1,501	1,417
<i>Depreciations and write-down included in operating expenses:</i>						
Property, plant and equipment	-101	-94	-287	-280	-392	-385
Intangible non-current assets from acquisitions	-98	-93	-283	-288	-375	-380
Other intangible non-current assets	-11	-12	-35	-32	-47	-44

Consolidated statement of comprehensive income

SEKm	Q3 2026	Q3 2025	Jan-Sep 2026	Jan-Sep 2025	Oct 2025- Sep 2026	Full year 2025
Profit for the period	128	82	386	302	646	562
<i>Components that may be reclassified to profit for the period:</i>						
Foreign currency translation differences for the period	133	-43	304	-213	178	-339
<i>Components that can not be reclassified to profit for the period:</i>						
Revaluations of defined benefit pension plans	-	-	-	-	4	4
Tax attributable to items not to be reversed in profit or loss	-	-	-	-	-1	-1
Other comprehensive income	133	-43	304	-213	181	-336
Total comprehensive income	261	39	690	89	827	226
<i>Attributable to:</i>						
Equity holders of the Parent Company	260	37	688	87	824	223
Non-controlling interests	1	2	2	2	3	3

Condensed consolidated balance sheet

SEKm	Sep 30 2026	Sep 30 2025	Dec 31 2025
Goodwill	6,041	5,523	5,449
Other intangible non-current assets	1,982	2,089	1,998
Property, plant and equipment	1,222	1,123	1,089
Financial non-current assets	48	30	26
Total non-current assets	9,293	8,765	8,562
Inventories	1,933	1,724	1,652
Current receivables	1,922	1,885	1,684
Cash and cash equivalents	477	286	813
Total current assets	4,332	3,895	4,149
Total assets	13,625	12,660	12,711
Total equity	5,958	5,308	5,447
Interest-bearing provisions	84	91	87
Non-interest-bearing provisions	344	332	324
Non-current interest-bearing liabilities	516	2,884	2,831
Non-current non-interest-bearing liabilities	34	32	31
Total non-current liabilities	978	3,339	3,273
Non-interest-bearing provisions	52	45	51
Current interest-bearing liabilities	4,623	2,132	1,943
Current non-interest-bearing liabilities	2,014	1,836	1,997
Total current liabilities	6,689	4,013	3,991
Total equity and liabilities	13,625	12,660	12,711

Condensed consolidated statement of changes in equity

SEKm	Jan 1 – Sep 30, 2026			Jan 1 – Dec 31, 2025		
	Equity excl. non-controlling interests	Non-controlling interests	Total equity	Equity excl. non-controlling interests	Non-controlling interests	Total equity
Amount at beginning of period	5,443	4	5,447	5,306	3	5,309
Share-based payments	5	–	5	5	–	5
Dividend	-182	-2	-184	-91	-2	-93
Total comprehensive income	688	2	690	223	3	226
Amount at the end of the period	5,954	4	5,958	5,443	4	5,447

Condensed consolidated statement of cash flows

SEKm	Q3 2026	Q3 2025	Jan-Sep 2026	Jan-Sep 2025	Oct 2025- Sep 2026	Full year 2025
Operating profit	221	165	686	600	1,079	993
Adjustment for items not included in cash flow	148	193	525	570	740	785
Interest paid	-46	-47	-131	-156	-177	-202
Interest received	9	-	14	1	17	4
Income tax paid	-38	-23	-154	-114	-257	-217
Changes in working capital	-58	-143	-435	-397	-9	29
Cash flow from operating activities	236	145	505	504	1,393	1,392
Net investments in non-current assets	-73	-58	-205	-180	-279	-254
Acquisitions and disposals	-77	-26	-400	-215	-432	-247
Change in other financial assets	1	0	0	0	4	4
Cash flow from investing activities	-149	-84	-605	-395	-707	-497
Dividend paid to shareholders	-	-	-182	-91	-182	-91
Dividend paid to non-controlling interests	-2	-	-2	-2	-2	-2
Borrowings/repayment of borrowings, net	-1	32	-1	139	-170	-30
Repayments on lease liability	-50	-45	-144	-137	-189	-182
Other financing activities	1	0	2	0	2	0
Cash flow from financing activities	-52	-13	-327	-91	-541	-305
Cash flow for the period	35	48	-427	18	145	590
Cash and cash equivalents at beginning of period	394	253	813	331	286	331
Exchange differences on cash and cash equivalents	48	-15	91	-63	46	-108
Cash and cash equivalents at end of the period	477	286	477	286	477	813

Key figures

	Rolling 12 months ending				
	Sep 30 2026	Dec 31 2025	Sep 30 2025	Dec 31 2024	Dec 31 2023
Net sales, SEKm	10,698	10,442	10,527	10,286	9,685
EBITDA, SEKm	1,893	1,802	1,644	1,533	1,504
EBITA, SEKm	1,501	1,417	1,266	1,159	1,135
EBITA margin, %	14.0	13.6	12.0	11.3	11.7
Adjusted EBITA, SEKm	1,311	1,259	1,266	1,165	1,015
Adjusted EBITA margin, %	12.3	12.1	12.0	11.3	10.5
Profit growth EBITA, %	19	22	16	2	-7
Profit growth adjusted EBITA, %	4	8	18	14	-10
Return on working capital (P/WC), %	63	62	55	51	50
Profit for the period, SEKm	646	562	396	254	192
Return on equity, %	11	11	8	5	4
Financial net liabilities, SEKm	4,746	4,048	4,821	4,920	5,192
Financial net liabilities/EBITDA, multiple	2.5	2.2	2.9	3.2	3.5
Net debt/equity ratio, multiple	0.8	0.7	0.9	0.9	1.0
Equity ratio, %	44	43	42	41	39
Average number of employees	2,336	2,292	2,296	2,311	2,284
Number of employees at end of the period	2,428	2,295	2,327	2,256	2,300

Key ratios per share

Attributable to owners of the parent

	Sep 30 2026	Dec 31 2025	Sep 30 2025	Dec 31 2024	Dec 31 2023
Earnings per share (EPS), before dilution, SEK ¹	5.28	4.59	3.23	2.06	1.56
Earnings per share (EPS), after dilution, SEK ¹	5.28	4.59	3.23	2.06	1.56
Cash flow per share from operating activities, SEK ¹	11.43	11.42	9.59	8.98	6.35
Shareholders' equity per share, SEK	48.86	44.67	43.53	43.54	40.69
Average number of shares after repurchases, '000s ¹	121,864	121,864	121,864	121,863	121,856
Average number of shares adjusted for repurchases and dilution, '000s ¹	121,870	121,884	121,872	121,863	121,861
Number of shares outstanding at end of the period, '000s	121,864	121,864	121,864	121,864	121,857
Number of shares outstanding at end of the period after dilution, '000s	121,870	121,884	121,872	121,864	121,857

¹Presented in rolling 12 months

Definitions can be found [here](#).

Parent company

The Parent Company's net sales for the interim period amounted to SEK 58 million (54) and profit after financial items totalled SEK -169 million (165). The Parent Company's net financial debt at the end of the interim period amounted to SEK 4,310 million (3,740). Share capital at the end of the interim period amounted to SEK 62 million (62).

Parent Company condensed income statement

SEKm	Q3 2026	Q3 2025	Jan-Sep 2026	Jan-Sep 2025	Oct 2025- Sep 2026	Full year 2025
Net sales	21	18	58	54	84	80
Administrative expenses	-28	-26	-91	-86	-122	-117
Operating profit	-7	-8	-33	-32	-38	-37
Interest income/expenses and similar items	-72	56	-136	197	-39	294
Profit after financial items	-79	48	-169	165	-77	257
Appropriations	-	-	-	-	-159	-159
Profit/loss before taxes	-79	48	-169	165	-236	98
Tax	-	-4	-	-19	19	0
Profit for the period	-79	44	-169	146	-217	98

Parent Company condensed balance sheet

SEKm	Sep 30 2026	Sep 30 2025	Dec 31 2025
Intangible non-current assets	0	0	0
Property, plant and equipment	0	0	0
Financial non-current assets	7,888	8,019	8,246
Total non-current assets	7,888	8,019	8,246
Current receivables	361	507	504
Cash and cash equivalents	22	-	395
Total current assets	383	507	899
Total assets	8,271	8,526	9,145
Restricted equity	62	62	62
Unrestricted equity	2,315	2,708	2,661
Total equity	2,377	2,770	2,723
Non-current interest-bearing liabilities	45	2,501	2,449
Non-current non-interest-bearing liabilities	3	2	3
Total non-current liabilities	48	2,503	2,452
Current interest-bearing liabilities	5,812	3,205	3,570
Current non-interest-bearing liabilities	34	48	400
Total current liabilities	5,846	3,253	3,970
Total equity and liabilities	8,271	8,526	9,145

Accounting policies

The interim report has been prepared in accordance with IFRS Accounting Standards, applying IAS 34 Interim Financial Reporting. Disclosures according to IAS 34.16A are presented not only in the financial statements and accompanying notes but also in other parts of the interim report. The Parent Company's interim report has been prepared in accordance with the Swedish Annual Accounts Act and the Securities Market Act which is in compliance with recommendation RFR 2 Accounting for Legal Entities. The same accounting principles and calculation methods as in AddLife's 2025 annual report have been applied in this interim report.

Comparative figures in the interim period for income statement items refer to the value for the period January – September, 2025 and for balance sheet items as of December 31, 2025, unless otherwise stated.

New or amended accounting policies from 2026 onwards

IFRS 18 and related amendments to other standards shall be applied for financial years beginning on or after 1 January 2027, with retrospective application. The new standard, which has been adopted by the EU, replaces IAS 1. The standard does not affect the recognition or measurement of items in the financial statements, but only results in changes to presentation and disclosures. An analysis of the effects of the standard on the Group is in progress. The standard has not been early adopted.

No other new or amended accounting standards or interpretations approved for application from 2026 are assessed to have any material effect on the Group's financial statements.

Information on Global Minimum Tax

The Group is subject to the OECD's Pillar II Model Rules. The Group's exposure to the Pillar II legislation has been calculated and analysed. The Group's assessment is that Pillar II has no material impact on the third quarter of 2026.

Risks and uncertainties

The geopolitical situation in Ukraine and the Middle East has not had any material direct impact on AddLife's financial reports during the interim period. However, continued geopolitical and trade policy uncertainty may indirectly affect the availability of products and components, supply chains, freight and energy costs, as well as public healthcare and research budgets.

AddLife's operations are primarily European, with approximately 95 percent of sales and 80 percent of purchases taking place in Europe, which limits direct exposure. At the same time, subcontractors and components further down the supply chain may be affected by tariffs, trade barriers, sanctions and international transport disruptions.

AddLife closely monitors developments relating to trade barriers, inflation, raw material, component, energy and freight costs, interest rates, as well as effects on customer demand and willingness to invest. For further information, reference is made to the section "Risks and uncertainties" in the administration report in AddLife's 2025 Annual Report. The Parent Company is indirectly affected by the above risks and uncertainties through its function within the Group.

Transactions with related parties

No related party transactions have taken place during the interim period that have had a material impact on the Group's financial position or results.

Financial instruments

Fair values on financial instruments

Fair value and carrying amount are recognised in the balance sheet as shown in the table below. For quoted securities, the fair value is determined on the basis of the asset's quoted price in an active market, level 1. At the reporting date, the Group had no items in this category. For currency contracts and embedded derivatives, the fair value is determined on the basis of observable market data, level 2. For contingent considerations, a cash flow-based valuation is performed, which is not based on observable market data, level 3. For the Group's other financial assets and liabilities, fair value is estimated to essentially correspond to the carrying amount.

SEKm	Sep 30, 2026			Dec 31, 2025		
	Carrying amount	Level 2	Level 3	Carrying amount	Level 2	Level 3
Derivatives measured at fair value through profit or loss	0	0	-	0	0	-
Total financial assets at fair value per level	0	0	-	0	0	-
Derivatives measured at fair value through profit or loss	0	0	-	0	0	-
Contingent considerations	225	-	225	124	-	124
Total financial liabilities at fair value per level	225	0	225	124	0	124

Contingent considerations

SEKm	Q3 2026	Q3 2025	Jan-Sep 2026	Jan-Sep 2025	Oct 2025-Sep 2026	Full year 2025
Amount at beginning of period	227	107	124	106	106	106
Acquisitions during the period	28	-	142	54	162	74
Consideration paid	-3	-	-23	-51	-23	-51
Revaluation through profit or loss	-33	-	-32	-	-32	-
Interest expenses	1	1	3	2	4	3
Exchange differences	5	-2	11	-5	8	-8
Amount at the end of the period	225	106	225	106	225	124

Pledged assets and contingent liabilities

SEKm	Sep 30 2026	Sep 30 2025	Dec 31 2025
Contingent liabilities	49	52	50

Nomination Committee

At the 2026 Annual General Meeting, it was resolved to authorize the Chairman of the Board to appoint, from among representatives of the five largest shareholders in terms of voting rights as of September 30, 2026, members who, together with the Chairman, shall constitute the Nomination Committee ahead of the forthcoming Board election. In accordance with this, the following persons have been appointed as members of the Nomination Committee: Johan Sjö, Chairman of the Board, Stefan Hedelius (appointed by Tom Hedelius), Håkan Roos (appointed by RoosGruppen AB), Roger Hedberg (appointed by Cliens Kapitalförvaltning), Andreas Wallheim (appointed by SEB Fonder), and Erik Eikeland (appointed by AMF Fonder). Information on how to contact the Nomination Committee is available on AddLife's website; add.life/investors/corporate-governance.

Significant events after the end of the interim period

Acquisition

In October, 85 percent of the shares in the German company Lehnem GmbH were acquired. Lehnem manufactures products and system solutions for accessible and functionally adapted bathrooms. The company has annual sales of approximately EUR 5 million and around 30 employees.

Bank loans

In October, the existing bank facilities were refinanced with a three-year term and two one-year extension options.

Stockholm, October 21, 2026

Fredrik Dalborg
President and CEO

Auditor's report

To the Board of Directors in AddLife AB (publ), corporate identity number 556995-8126

Introduction

We have conducted a limited review of the condensed interim financial information (interim report) for AddLife AB (publ) as of September 30, 2026, and the nine-month period ending on that date. The Board of Directors and the managing director are responsible for preparing and presenting this interim report in accordance with IAS 34 and the Swedish Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our limited review.

The focus and scope of the limited review

We have conducted our limited review in accordance with the International Standard on Review Engagements ISRE 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity." A limited review consists of making inquiries, primarily of persons responsible for financial and accounting matters, performing analytical procedures, and other review procedures. A limited review has a different focus and a significantly smaller scope compared to the focus and scope of an audit conducted in accordance with ISA and generally accepted auditing standards. The review procedures taken in a limited review do not enable us to obtain the assurance that we would become aware of all significant matters that might have been identified in an audit. Therefore, the conclusion expressed based on a limited review does not have the assurance that a conclusion expressed based on an audit has.

Conclusion

Based on our limited review, nothing has come to our attention that causes us to believe that the interim report is not, in all material respects, prepared for the group in accordance with IAS 34 and the Annual Accounts Act and for the parent company in accordance with the Annual Accounts Act.

Stockholm, October 21, 2026

Öhrlings PricewaterhouseCoopers AB

Fredrik Göransson
Authorized Public Accountant

Definitions

Number of employees at the end of the period	The number of employees in the Group at the end of the reporting period, taking into account the degree of employment. <i>This measure is used to know how many employees the Group has at the end of the reporting period.</i>
Return on equity	Profit/loss after tax attributable to shareholders, as a percentage of shareholders' proportion of average equity. <i>Return on equity measures from an ownership perspective the return that is given on the owners' invested capital.</i>
Return on working capital (P/WC)	EBITA in relation to average working capital. <i>P/WC is used to analyse profitability and encourage high EBITA earnings and low working capital requirements.</i>
EBITA	Operating profit before amortisation and write-down of intangible assets. <i>EBITA is used to assess operating profitability excluding the impact of amortisation and impairment of intangible assets, primarily arising from acquisitions.</i>
EBITA margin	EBITA as a percentage of net sales. <i>The EBITA margin is used to analyze value creation from the operating activities.</i>
EBITDA	Operating profit before depreciation, amortisation and write-down. <i>EBITDA is used to assess earnings generation before depreciation, amortisation and impairment, and as a measure closely reflecting operating cash flow before changes in working capital and investments.</i>
Equity per share	Shareholders' proportion of equity divided by the number of shares outstanding at the end of the reporting period.
Financial net	Financial income minus financial expenses. <i>Used to describe the development of the Group's financial activities.</i>
Acquired growth	Changes in net sales attributable to business acquisitions compared to the same period the previous year. <i>Acquired growth is used as a component to describe the development of the Group's net sales, where acquired growth is distinguished from organic growth, divestments, and currency effects.</i>
Adjusted EBITA	EBITA excluding one-off costs. <i>Increases the comparability of EBITA over time as it is adjusted for the impact of items considered to be non-recurring in nature and therefore do not reflect the underlying operations.</i>
Adjusted EBITA margin	Adjusted EBITA in relation to net sales. <i>Used to measure the company's profitability excluding the impact of items considered to be non-recurring in nature and therefore do not reflect the underlying operations.</i>
One-off costs	Primarily refers to restructuring costs and revaluation of contingent considerations. Other non-recurring items may also be reported as one-off costs if this provides a more accurate view of the underlying operating result.

Cash flow from operating activities per share	Cash flow from operating activities, divided by the average number of shares. <i>The measure is used to allow investors to easily analyze the amount of surplus from ongoing operations generated per share.</i>
Net investments in fixed assets	Investments in fixed assets minus sales of fixed assets. <i>The measure is used to analyze the Group's investments in the renewal and development of tangible fixed assets.</i>
Net debt/equity ratio	Financial net liabilities in relation to shareholders' equity. <i>Net debt/equity ratio is used to analyse financial risk.</i>
Organic growth	Changes in net sales excluding currency effects and acquisitions/divestments compared to the same period the previous year. <i>Organic growth is used to analyze the underlying sales growth driven by changes in volume, product range, and price for similar products between different periods.</i>
Profit after financial items	Profit/loss for the period before tax. <i>Used to analyse the business' profitability including financial activities</i>
Earnings per share	Shareholders' share of the period's result divided by the number of shares outstanding at the end of the reporting period.
Earnings per share before dilution	Shareholders' share of the period's result divided by the average number of outstanding shares.
Earnings per share after dilution	Shareholders' share of the period's result divided by a weighted average of the number of outstanding shares, adjusted for the additional number of shares upon the exercise of outstanding options.
Profit growth EBITA	The period's EBITA decreased by previous period's EBITA divided by the previous period's EBITA. <i>Profit growth EBITA is used to analyse asset-creating generated from operational activities.</i>
Financial net liabilities	Interest-bearing liabilities and interest-bearing provisions, less cash and cash equivalents. <i>Net debt is used to monitor debt development and analyse financial leverage and any necessary refinancing.</i>
Financial net liabilities/EBITDA	Financial net liabilities divided by EBITDA. <i>Financial net liabilities compared with EBITDA provides a key financial indicator for financial net liabilities in relation to cash-generated operating profit; i.e., an indication of the ability of the business to pay its debts. This measure is generally used by financial institutions as a measure of creditworthiness.</i>
Working capital	Sum of inventories and accounts receivable, less accounts payable. In the calculation of P/WC, average working capital is used. <i>Working capital is used to analyse how much working capital is tied up in the business.</i>
Equity ratio	Equity, including non-controlling interests, as a percentage of total assets. <i>The equity ratio is used to analyse financial risk and shows how much of the assets are financed with equity.</i>

Alternative performance measures

This report contains financial key figures in accordance with the frameworks applied by AddLife, which are based on IFRS. In addition, there are alternative performance measures (APM) that cannot be directly extracted or derived from the financial statements. These key figures are essential for understanding and evaluating AddLife's operations and financial position. They should not be seen as a replacement for the measures defined according to IFRS but rather as a complement to the financial reporting. Since not all companies calculate financial measures in the same way, these are not always comparable with measures used by other companies. The key figures are presented below and commented on in other parts of the interim period.

Return on equity

SEKm	Sep 30 2026	Sep 30 2025	Full year 2025
Profit/loss for the period attributable to shareholders (rolling 12 months)	644	394	560
Average equity	5,612	5,232	5,293
Return on equity, %	11	8	11

Return on working capital (P/WC)

SEKm	Sep 30 2026	Sep 30 2025	Full year 2025
EBITA (rolling 12 months)	1,501	1,266	1,417
Inventories, average	1,771	1,746	1,713
Accounts receivable, average	1,613	1,579	1,586
Accounts payable, average	-1,005	-1,016	-1,013
Working capital, average	2,379	2,309	2,286
Return on working capital, %	63	55	62

EBITA and EBITDA

SEKm	Q3 2026	Q3 2025	Jan-Sep 2026	Jan-Sep 2025	Oct 2025- Sep 2026	Full year 2025
Operating profit	221	165	686	600	1,079	993
Amortisation and impairment of intangible assets	109	105	318	320	422	424
EBITA	330	270	1,004	920	1,501	1,417
Depreciation and impairment of tangible assets	101	94	287	280	392	385
EBITDA	431	364	1,291	1,200	1,893	1,802

Adjusted EBITA

SEKm	Q3 2026	Q3 2025	Jan-Sep 2026	Jan-Sep 2025	Oct 2025- Sep 2026	Full year 2025
EBITA	330	270	1,004	920	1,501	1,417
<i>One-off costs</i>						
Sale of business	-	-	-	-	-158	-158
Revalued contingent consideration	-32	-	-32	-	-32	-
Adjusted EBITA	298	270	972	920	1,311	1,259

EBITA margin / Adjusted EBITA margin

	Q3 2026	Q3 2025	Jan-Sep 2026	Jan-Sep 2025	Oct 2025- Sep 2026	Full year 2025
SEKm						
EBITA	330	270	1,004	920	1,501	1,417
Net sales	2,599	2,429	7,965	7,709	10,698	10,442
EBITA margin, %	12.7	11.1	12.6	11.9	14.0	13.6
Adjusted EBITA	298	270	972	920	1,311	1,259
Adjusted EBITA margin, %	11.5	11.1	12.2	11.9	12.3	12.1

Organic growth

	Labtech		Medtech		The Group ¹	
%	Q3 2026	Q3 2025	Q3 2026	Q3 2025	Q3 2026	Q3 2025
Total growth	8.5	6.3	6.0	2.1	7.0	3.6
(-) Currency effect	1.1	-2.4	1.0	-3.3	1.0	-3.0
(-) Acquired growth	5.5	-	1.4	1.5	2.9	1.0
Organic growth	1.9	8.7	3.6	3.9	3.1	5.6

	Labtech		Medtech		The Group ¹	
SEKm	Q3 2026	Q3 2025	Q3 2026	Q3 2025	Q3 2026	Q3 2025
Total growth	77	54	93	30	170	85
(-) Currency effect	10	-20	17	-50	24	-69
(-) Acquired growth	50	-	21	22	71	22
Organic growth	17	74	55	58	75	132

	Labtech		Medtech		The Group ¹	
%	Jan-Sep 2026	Jan-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Sep 2026	Jan-Sep 2025
Total growth	5.0	8.4	2.3	0.3	3.3	3.2
(-) Currency effect	-0.7	-2.5	-1.4	-2.6	-1.2	-2.5
(-) Acquired growth	3.5	1.9	1.7	1.0	2.4	1.3
Organic growth	2.2	9.0	2.0	1.9	2.1	4.4

	Labtech		Medtech		The Group ¹	
SEKm	Jan-Sep 2026	Jan-Sep 2025	Jan-Sep 2026	Jan-Sep 2025	Jan-Sep 2026	Jan-Sep 2025
Total growth	145	224	112	15	256	241
(-) Currency effect	-20	-65	-68	-122	-89	-186
(-) Acquired growth	102	51	83	47	185	98
Organic growth	63	238	97	90	160	329

¹The Group includes eliminations

Profit growth EBITA / Profit growth adjusted EBITA

	Sep 30 2026	Sep 30 2025	Full year 2025
SEKm			
EBITA (rolling 12 months)	1,501	1,266	1,417
(-) Previous year's EBITA (rolling 12 months)	1,266	1,091	1,159
EBITA growth	235	175	258
Profit growth EBITA, %	19	16	22
Adjusted EBITA (rolling 12 months)	1,311	1,266	1,259
(-) Previous year's adjusted EBITA (rolling 12 months)	1,266	1,077	1,165
Adjusted EBITA growth	45	189	94
Profit growth adjusted EBITA, %	4	18	8

Financial net liabilities and Net debt/equity ratio

SEKm	Sep 30 2026	Sep 30 2025	Full year 2025
Borrowing	4,343	4,407	4,146
Cash and cash equivalents	-477	-286	-813
Financial net debt	3,866	4,121	3,333
Pension liability	57	61	58
Lease liability	571	503	504
Contingent considerations	225	106	124
Provisions	27	30	29
Net interest-bearing debt	4,746	4,821	4,048
Total equity	5,958	5,308	5,447
Net debt/equity ratio, multiple	0.8	0.9	0.7

Financial net liabilities/EBITDA

SEKm	Sep 30 2026	Sep 30 2025	Full year 2025
Net interest-bearing debt	4,746	4,821	4,048
EBITDA (rolling 12 months)	1,893	1,644	1,802
Financial net liabilities/EBITDA, multiple	2.5	2.9	2.2

Equity ratio

SEKm	Sep 30 2026	Sep 30 2025	Full year 2025
Total equity	5,958	5,308	5,447
Total assets	13,625	12,660	12,711
Equity ratio, %	44	42	43

The share

The share capital at the end of the interim period amounted to SEK 62 million (62).

The number of repurchased own shares amounts to 586,189 Class B, corresponding to 0.48 percent of the total number of shares and 0.36 percent of the votes. The average purchase price for shares held in treasury amounts to SEK 100.56 per share. The average number of treasury shares held during the interim period was 586,189 (586,189). The share price at September 30, 2026, was SEK 172.00.

AddLife has an outstanding incentive programme based on call options, corresponding to a total of 205,800 B shares. Issued call options on repurchased shares have resulted in a calculated dilution effect based on average share price for the interim period of approximately 0.0 percent (0.0). During the interim period, the 2022/2026 programme expired without impact, as the exercise price during the exercise period exceeded the share price.

AddLife has three outstanding incentive programmes based on performance shares corresponding to a maximum of 257,758 of the Company's Class B shares, which represents approximately 0.2 percent of the total number of shares. Participants receive performance shares provided that employment continues, the investment shares are retained, and the performance conditions are met. These are based on the average annual profit growth (EBITA) during the respective measurement period, as well as sustainability-related goals.

During the interim period, SEK 5 million (2) has been expensed as a result of the program.

On September 30, 2026, the number of shareholders amounted to 10,477, of which 67.9 percent are Swedish owners with respect to capital share. The 10 largest shareholders controlled 52.32 percent of the capital and 62.94 percent of votes.

Incentive programmes based on call options

Outstanding programmes	Number of warrants	Corresponding number of shares	Percentage of total number of shares, %	Exercise price	Exercise period
2023/2027	205,800	205,800	0.2	155.99	Jun 1, 2026 – Feb 26, 2027
Total	205,800	205,800			

Incentive programme based on performance shares

Outstanding programmes	Number of investment shares	Corresponding maximum number of performance shares	Percentage of total number of shares, %	Vesting period	Measurement period
LTIP 2026	18,923	88,192	0.1	Aug 31, 2026 – Aug 31, 2029	Jan 1, 2026 – Dec 31, 2028
LTIP 2025	13,064	61,806	0.1	Aug 31, 2025 – Aug 31, 2028	Jan 1, 2025 – Dec 31, 2027
LTIP 2024	22,565	107,760	0.1	Aug 31, 2024 – Aug 31, 2027	Jan 1, 2024 – Dec 31, 2026
Total	54,552	257,758			

Shareholders

Shareholders 2026-09-30	Class A-shares	Class B-shares	Share in %	
			of capital	of votes
RoosGruppen AB	2,256,408	3,838,841	4.98	16.14
Tom Hedelius	2,066,572	–	1.69	12.63
AMF Fonder	–	11,730,603	9.58	7.17
SEB Fonder	–	9,704,361	7.93	5.93
Cliens Fonder	–	7,012,932	5.73	4.29
Odin Fonder	–	6,600,008	5.39	4.03
Fjärde AP-fonden	–	5,440,000	4.44	3.33
Fidelity Mutual Funds	–	5,359,566	4.38	3.28
Swedbank Robur Fonder	–	5,309,956	4.34	3.25
Vanguard Funds	–	4,727,562	3.86	2.89
Total the 10 biggest shareholders	4,322,980	59,723,829	52.32	62.94
Other shareholders	249,816	57,567,436	47.20	36.70
Total outstanding shares	4,572,796	117,291,265	99.52	99.64
Repurchased own shares Class B	–	586,189	0.48	0.36
Total registered shares	4,572,796	117,877,454	100.00	100.00

Source: Euroclear

For further information about the share, see AddLife's website: add.life/en/investors/the-share

Video conference

Investors, analysts and the media are invited to a video conference where President and CEO Fredrik Dalborg and CFO Christina Rubenhag will present the interim report. The presentation will be held in English and takes about 20 minutes, after which there will be an opportunity to ask questions. It will be recorded and made available online.

The video conference will be held at 9:00 a.m. CEST on October 21, 2026.

If you wish to participate via video conference, [please follow this link>>](#)

The presentation is also available on [AddLife YouTube >>](#)

Financial calendar

- Year-end report for January 1 – December 31, 2026, will be published on February 3, 2027
- The interim report for January 1 – March 31, 2027, will be published on April 29, 2027
- The Annual General Meeting (AGM) of AddLife AB (publ) will be held on May 4, 2027, at 4:00 p.m. CEST, Stockholm
- The interim report for January 1 – June 30, 2027, will be published on July 16, 2027
- The interim report for January 1 – September 30, 2027, will be published on October 22, 2027

For further information, please contact:

Fredrik Dalborg, President and CEO, +46 70 516 09 01

Christina Rubenhag, CFO, +46 70 546 72 22

AddLife's interim report is published in Swedish and in an English translation. The Swedish version takes precedence in the event of any discrepancies between the two versions.

VISION

To improve people's lives by being a leading and value-creating partner in Life Science.

BUSINESS IDEA


AddLife adds value for its customers operating in the healthcare sector, from research to care. This is done by offering high-quality, cost-effective service and product solutions to both the private and public sectors in Europe.

CORE VALUES

Simplicity – Responsibility – Commitment – Innovation. The Group's core values guide AddLife's entrepreneurial business model.

ADDLIFE IN BRIEF

AddLife is an independent partner in the Life Science industry that offers high-quality products, services and advice to both the private and public sectors in Europe. AddLife has 2,300 employees in about 85 operating subsidiaries. The Group currently has net sales of more than SEK 10 billion. AddLife shares are listed on Nasdaq Stockholm.



This information is information that AddLife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 7:45 a.m. CEST on October 21, 2026.

AddLife AB (publ), Box 3145, Brunkebergstorg 5, SE-103 62 Stockholm. info@add.life, www.add.life, corporate identity number 556995-8126